Post by
ualcin1 on Oct 30, 2020 11:09am
Hi sah1
Hello sah1. Can we get your comments on this new development, which you anticipated in your comment yesterday at 1:55 pm?
Comment by
ualcin1 on Oct 30, 2020 1:50pm
Thank you sah1. I can't say I'm very happy about it either. On September 24th, in your 8:44 am post, you anticipated a sp of about $25 on FDA approval of the BLA, based on the assumptions you described in that post at the time. With this new development, and the dilution it will cause, what is your new sp hypothesis?
Comment by
sah1 on Oct 30, 2020 2:07pm
The value of the Ryplazim platform and voucher remains the same. So $600M divided by 36M (assuming warrants exercised) equates to about $16. This gives zero value to the small molecule division which is consistent with current market pricing.
Comment by
ualcin1 on Oct 30, 2020 2:42pm
Thank you sah1. It would be interesting to know the opinion of the lawyers who initiated the oppression remedy against Prometic as a result of the financial restructuring of 2019...
Comment by
GunnerG on Oct 30, 2020 3:29pm
You say in a later post you used Stockman's numbers, I think you used mine. (Stockman's) 23.6M OS + 6.3M = 29.9M OS. (GunnerG) 23.6M OS + 12.6 = 36.2M OS
Comment by
GunnerG on Oct 30, 2020 4:25pm
Yes the dollar value of $30M is explicit. Its the warrants and shares I am talking about. ????
Comment by
GunnerG on Oct 30, 2020 5:25pm
Thanks Stockman, your english is good but not good enough to interpret the meaning of the NR. Why you brought up the $30M when I was talking about shares outstanding, I have no idea.